您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Pep2m,myristoylated TFA
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Pep2m,myristoylated TFA
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
包装:5mg
市场价:3150元

产品介绍
Pep2m,myristoylatedTFA(Myr-Pep2mTFA)是一种细胞通透性肽。Pep2m,myristoylatedTFA能破坏蛋白激酶ζ(PKMζ)下游靶点NSF/GluR2相互作用。PKMζ具有自主活性的PKC同工酶。
别名Myr-Pep2m TFA
分子式C65H119F3N18O16S
分子量1497.83
储存条件-20℃, away from moisture
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Pep2m, myristoylated TFA (Myr-Pep2m TFA) is a cell-permeable peptide. Pep2m, myristoylated TFA can disrupt the protein kinase ζ (PKMζ) downstream targets, N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions. PKMζ is an autonomously active isozyme of protein kinase C (PKC)[1][2].

Pep2m, myristoylated TFA (10 μM) blocks PKMζ-mediated AMPA receptor (AMPAR) potentiation[1].Pep2m, myristoylated TFA does not block the increase of PKMζ in the hippocampal slices during long-term potentiation (LTP) maintenance, indicating that blocking NSF/GluR2 interactions do not prevent the induction of PKMζ synthesis[1].Pep2m, myristoylated TFA blocks NSF/GluR2-mediated AMPAR trafficking, and reverses persistent potentiation at both the strongly stimulates synapses and the weakly stimulats synapses that underwent synaptic tagging and capture[1].

Pep2m, myristoylated TFA (10 µg) results in an increase in paw withdrawal thresholds (PWTs) on nociceptive responses in the formalin test[2]. Animal Model: Female and male Long-Evans hooded rats (8 weeks)[2]

[1]. Yudong Yao, et al. PKMζ Maintains Late Long-Term Potentiation by N-Ethylmaleimide-Sensitive Factor/GluR2-Dependent Trafficking of Postsynaptic AMPA Receptors. J Neurosci. 2008 Jul 30; 28(31): 7820-7827. [2]. Nicole C George, et al. Sex differences in the contributions of spinal atypical PKCs and downstream targets to the maintenance of nociceptive sensitization. Mol Pain. 2019; 15: 1744806919840582.